Overview

A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease

Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
0
Participant gender:
Female
Summary
To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus oral metronidazole in uncomplicated pelvic inflammatory disease (PID)
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones
Levofloxacin
Metronidazole
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ofloxacin
Criteria
Inclusion Criteria:

- Diagnosis of uncomplicated PID based on the absence of pelvic or tubo-ovarian abscess
at pelvic ultrasound and/or laparoscopic examination.

Exclusion Criteria:

- Subjects with impaired liver and renal function; known hypersensitivity to study
drugs, related compounds or any of the excipients.